Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Yale University
Northwestern University
National Institutes of Health Clinical Center (CC)